title: Over-expression of LAPTM4B is associated with poor prognosis and chemotherapy resistance in stages III and IV epithelial ovarian cancer.
abstract: BACKGROUND
  The purpose of this study was to determine whether LAPTM4B over-expression is associated with the prognosis and chemotherapy resistance in patients with stages III and IV epithelial ovarian carcinoma, i.e., patients with peritoneal metastasis or lymph node metastasis of epithelial ovarian carcinoma.
  
  
  METHODS
  LAPTM4B expression was evaluated in 10 normal ovarian and 113 stages III-IV ovarian carcinomas specimens by Western blotting analyses and immunohistochemistry. Univariate and multivariate analyses were performed to determine the association between LAPTM4B expression and prognosis and the relationship between LAPTM4B over-expression and chemotherapy resistance.
  
  
  RESULTS
  Western blotting analysis demonstrated that LAPTM4B was overexpressed in ovarian cancers, and immunohistochemistry results revealed that 80 patients were LAPTM4B over-expression. The five-year overall survival (OS) rates for patients with high LAPTM4B expression and low LAPTM4B expression were 27.36% and 90.7%, respectively (hazard ratio = 20.611, 95% CI: 5.916-71.808, P < 0.0001). The five-year progression-free survival (PFS) rate was 17.68% for patients in the high-expression group and 84.42% for patients in the low-expression group (hazard ratio = 17.852, 95% CI: 6.31-5.935, P < 0.0001); The presence of chemotherapy resistance was significantly associated with LAPTM4B expression (OR: 36.609, 95% CI: 4.737-282.941, P = 0.0006).
  
  
  CONCLUSIONS
  LAPTM4B over-expression is an independent factor in stages III-IV epithelial ovarian carcinoma prognosis and chemotherapy resistance, and it may be an important potential biomarker.
authors.affiliation: Department of Gynecology Oncology, The Tumor Hospital of Harbin Medical University, Harbin, China.
authors.forename: Mingzhu
authors.initials: M
authors.lastname: Yin
authors.forename: Cong
authors.initials: C
authors.lastname: Li
authors.forename: Xia
authors.initials: X
authors.lastname: Li
authors.forename: Ge
authors.initials: G
authors.lastname: Lou
authors.forename: Bing
authors.initials: B
authors.lastname: Miao
authors.forename: Xiaodong
authors.initials: X
authors.lastname: Liu
authors.forename: Fanling
authors.initials: F
authors.lastname: Meng
authors.forename: Haiyu
authors.initials: H
authors.lastname: Zhang
authors.forename: Xiuwei
authors.initials: X
authors.lastname: Chen
authors.forename: Meng
authors.initials: M
authors.lastname: Sun
authors.forename: Qiu
authors.initials: Q
authors.lastname: Ling
authors.forename: Rouli
authors.initials: R
authors.lastname: Zhou
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D002288:Adenocarcinoma, Mucinous / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects*; D014408:Biomarkers, Tumor / Q000378:metabolism*; D015153:Blotting, Western; D015331:Cohort Studies; D018284:Cystadenocarcinoma, Serous / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D019008:Drug Resistance, Neoplasm; D016889:Endometrial Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007124:Immunoenzyme Techniques; D008207:Lymphatic Metastasis; D008565:Membrane Proteins / Q000378:metabolism*; D008875:Middle Aged; D009367:Neoplasm Staging; D015513:Oncogene Proteins / Q000378:metabolism*; D010051:Ovarian Neoplasms / Q000188:drug therapy / Q000378:metabolism* / Q000473:pathology; D010534:Peritoneal Neoplasms / Q000188:drug therapy / Q000378:metabolism / Q000556:secondary; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D014408:Biomarkers, Tumor; C477083:LAPTM4B protein, human; D008565:Membrane Proteins; D015513:Oncogene Proteins